Anti-cancer Potentiality of Saffron Against Hepatocellular Carcinoma

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 30, 2024

Primary Completion Date

May 1, 2025

Study Completion Date

October 1, 2025

Conditions
Hepatocellular Carcinoma
Interventions
DIETARY_SUPPLEMENT

Saffranal

HCC patients will receive 50 mg safranal regimen in dose of once per day for six months.

DIETARY_SUPPLEMENT

Placebo

HCC patients will receive Placebo in dose of once per day for six months.

Trial Locations (2)

123456

Amal A. Elkholy, Al ‘Abbāsīyah

Dermatology Clinic of National Hepatology and Tropical Medicine Research Institute, Cairo

All Listed Sponsors
collaborator

Mohamed, Ahmed A., M.D.

INDIV

collaborator

Amr Amin College of Medicine, University of Sharjah, Sharjah 27272, UAE.

UNKNOWN

collaborator

Ahmed Cordie Endemic Medicine department, Cairo University Hospitals.

UNKNOWN

collaborator

Nouran Mohamed Endemic Medicine department, Cairo University Hospitals.

UNKNOWN

collaborator

Gamal Esmat Faculty of Biotechnology, Misr University for Science and Technology, Giza, Egypt.

UNKNOWN

lead

Ain Shams University

OTHER

NCT06464380 - Anti-cancer Potentiality of Saffron Against Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter